Skyhawk, Therapeutics

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk

Skyhawk Therapeutics Massachusetts


https://twitter.com/Skyhawk_Tx

SKYHAWK MEDIA CONTACT:
Maura McCarthy maura@skyhawktx.com

Logo - https://mma.prnewswire.com/media/710814/Skyhawk_Therapeutics_Logo.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/skyhawk-therapeutics-has-advanced-to-the-multiple-ascending-dose-portion-of-its-phase-1-study-evaluating-sky-0515-a-rna-targeting-small-molecule-for-huntingtons-disease-302074198.html

en | CA00765C1086 | SKYHAWK | boerse | 67922952 |